4 Doses
per Year

Convenient dosing schedule every 12 weeks after 2 starter doses at Weeks 0 and 4.

Janssen CarePath FOR STELARA® (USTEKINUMAB)

Janssen CarePath helps your patients start and stay on STELARA® as you've prescribed.

Resources

To support your practice and help your patients start and stay on STELARA®.

STELARA®:

A GROWING LEGACY IN THE TREATMENT OF PLAQUE PSORIASIS

PSO 15

STELARA® has been clinically studied for 15 years.1

PSO 71

More than 7100 dermatologists have prescribed STELARA® in the United States.ǁ

+135K

More than 135,000 patients treated in the United States.

PSO 551

More than 551,000 patient-years since first exposure worldwide.#

NATIONAL PSORIASIS FOUNDATION®

Recognized STELARA® as a first-line systemic in moderate to severe plaque psoriasis.2**††

*Janssen Link will also provide STELARA® for the next program year if your patients remain eligible and you want their treatment to continue.

Including UnitedHealthcare®, UHC West®, OptumRx®, Aetna® (pharmacy benefit only), Anthem®, Express Scripts®, and Humana® (medical benefit only); as of September 8, 2016.

A phase 1 clinical trial of STELARA® was initiated in 2001 in patients with moderate to severe plaque psoriasis. Phase 3, double-blind, placebo-controlled, multicenter trials PHOENIX 1 and PHOENIX 2 began in 2005 and 2006, respectively.

§IMS Health-Xponent data. Prescribers who have written at least one prescription for STELARA® in the United States from October 2009 to April 2016.3

Reflects usage across all lines of therapy.

More than 135,000 patients treated with STELARA® in the United States from September 2009 to February 2016. Estimations are based on calculations using product utilization data collected in the United States for STELARA® to determine patient type, average dose per administration, total number of administrations, and patient persistency rates.3

#Based on worldwide estimated number of patient-years from launch through December 2015. Patient-years since first exposure were estimated by calculations using STELARA® distribution date to determine average yearly dose while considering regional estimates of patient compliance to dosing regimen.3

**The National Psoriasis Foundation does not endorse any specific medications, products, equipment, or treatment for psoriasis.

††The National Psoriasis Foundation—in its 2012 published guidelines for treating moderate to severe plaque psoriasis—supports the use of STELARA® as a first-line systemic therapy.

 


References: 1. Data on file. Janssen Biotech, Inc. 2. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95-102.